{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:35:52Z","timestamp":1790908552210,"version":"4.1.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"7-8","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Res Treat"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Introduction:&lt;\/i&gt;&lt;\/b&gt; Real-world data on usage of 1st-, 2nd-, and 3rd-generation tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) are scarce. This study therefore aimed to analyze the use of different TKIs used in 1st- and 2nd-line treatment and the frequency of TKI switches in CML. &lt;b&gt;&lt;i&gt;Methods:&lt;\/i&gt;&lt;\/b&gt; This observational study was based on the InGef research database, an anonymized representative claims dataset in Germany (&lt;i&gt;n&lt;\/i&gt; = 4 million). An incidence and prevalence patient CML cohort was followed for 5 and 3 years. Analyses regarding incidence, prevalence, and therapy distribution were performed descriptively. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; 151 patients were included in the incidence and 636 patients in the prevalence cohort. This resulted in an incidence of 1.8 (95% confidence interval [CI]: 1.34\u20132.20) and a prevalence of 14.9 (95% CI: 13.70\u201316.03) per 100,000 inhabitants. For the incidence cohort, data on 1st-line therapy were available for 124 patients and distributed across imatinib (&lt;i&gt;N&lt;\/i&gt; = 52), nilotinib (&lt;i&gt;N&lt;\/i&gt; = 44), dasatinib (&lt;i&gt;N&lt;\/i&gt; = 12), chemotherapies as hydroxycarbamide (&lt;i&gt;N&lt;\/i&gt; = 11), and ponatinib\/bosutinib (&lt;i&gt;N&lt;\/i&gt; = 5). Twenty-six percent of patients switched TKI therapy at least once in 3 years. In the prevalence cohort, 423 patients (66.5%) had claims on existing or newly emerged cardiovascular diseases (CDs). No significant differences (&lt;i&gt;p&lt;\/i&gt; = 0.32) between TKIs in patients with CD were found. &lt;b&gt;&lt;i&gt;Discussion:&lt;\/i&gt;&lt;\/b&gt; Every fourth patient switched TKI therapy within the first 3 years after treatment initiation. Switches were more likely when hints of disease progression or intolerability were observable in the database. <\/jats:p>","DOI":"10.1159\/000524284","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T06:50:03Z","timestamp":1648450203000},"page":"400-407","source":"Crossref","is-referenced-by-count":15,"title":["Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis"],"prefix":"10.1159","volume":"45","author":[{"given":"Susanne","family":"Sau\u00dfele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kohlbrenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Vogelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tino","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.1.99"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1379074"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14694\/edbook_am.2015.35.e381"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/2325967119877847"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3895"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2155-y"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0047-5"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217697484"}],"container-title":["Oncology Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/524284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/524284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:00:30Z","timestamp":1745424030000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000524284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":9,"journal-issue":{"issue":"7-8","published-online":{"date-parts":[[2022,8,4]]},"published-print":{"date-parts":[[2022,8,11]]}},"URL":"https:\/\/doi.org\/10.1159\/000524284","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.19419347","asserted-by":"subject"}]},"ISSN":["2296-5270","2296-5262"],"issn-type":[{"value":"2296-5270","type":"print"},{"value":"2296-5262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}